{"id":4221,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2014-01-31","marketCap":3.8295838832855225,"name":"Trevena Inc","phone":"16103548840","outstanding":18.34000015258789,"symbol":"TRVN","website":"https://www.trevena.com/","industry":"Biotechnology"},"price":4.53275,"year":2024,"month":8,"day":14,"weekday":"Wednesday","title":"The Role of Trevena Inc Stock in a Diversified Investment Portfolio","date":"2024-08-14","url":"/posts/2024/08/14/TRVN","content":[{"section":"Introduction","text":"When building a diversified investment portfolio, it's important to include a variety of different asset classes, such as stocks, bonds, and real estate. Each asset class performs differently under various market conditions, and including a mix of assets can help reduce the overall risk and increase potential returns. Trevena Inc stock can be a valuable addition to a diversified portfolio."},{"section":"Growth Potential","text":"Trevena Inc is a pharmaceutical company that focuses on developing innovative therapies. By investing in Trevena Inc stock, investors have the opportunity to participate in the potential growth and success of the company. If Trevena Inc develops and successfully brings a new drug or treatment to market, the stock price may increase, generating positive returns for investors."},{"section":"Diversification Benefit","text":"Including Trevena Inc stock in a diversified portfolio can also provide diversification benefits. Diversification means spreading investments across different assets to reduce exposure to any single investment. By including Trevena Inc stock alongside other stocks, bonds, and assets in a portfolio, investors can potentially reduce their overall risk. This is because the stock's performance may not necessarily move in the same direction as the other assets in the portfolio. If one investment is underperforming, the positive performance of Trevena Inc stock can help offset some of the losses and stabilize the overall portfolio."},{"section":"Risk Considerations","text":"It's important to note that investing in individual stocks, including Trevena Inc, carries inherent risks. The stock price can be influenced by a variety of factors, such as market conditions, company performance, and industry trends. This means that the stock price can be volatile and may experience significant fluctuations. Investors should carefully evaluate their risk tolerance and consider diversifying their investments beyond just Trevena Inc stock."},{"section":"Conclusion","text":"Including Trevena Inc stock in a diversified investment portfolio can provide both growth potential and diversification benefits. As a pharmaceutical company, Trevena Inc offers the potential for positive returns if successful in developing new treatments. Additionally, the stock's performance may not correlate with other assets in the portfolio, providing diversification benefits. However, it's important for investors to be aware of the inherent risks associated with investing in individual stocks and consider diversifying their investments across various asset classes."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1723479844,"headline":"Upcoming Stock Splits This Week (August 12 to August 16) – Stay Invested","id":129312730,"image":"https://media.zenfs.com/en/tipranks_452/a2b94407aff74838ab1b3b639520db5d","symbol":"TRVN","publisher":"Yahoo","summary":"These are the upcoming stock splits for the week of August 12 to August 16, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate). In t","url":"https://finance.yahoo.com/news/upcoming-stock-splits-week-august-162404302.html"},{"category":"company","date":1723445400,"headline":"Trevena trading halted, news pending","id":129333804,"image":"","symbol":"TRVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597954503"},{"category":"company","date":1723176480,"headline":"Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket","id":129261373,"image":"","symbol":"TRVN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593747100"},{"category":"company","date":1723147500,"headline":"Trevena Announces Reverse Stock Split","id":129256269,"image":"https://s.yimg.com/ny/api/res/1.2/2gvMNNygNV5e1AaspcMgbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0yNzc-/https://media.zenfs.com/en/globenewswire.com/e0fcc3502771507a450882b6a41df7a8","symbol":"TRVN","publisher":"Yahoo","summary":"CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the “Amendment”) to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET on Tuesda","url":"https://finance.yahoo.com/news/trevena-announces-reverse-stock-split-200500568.html"},{"category":"company","date":1723121880,"headline":"TRVN Stock Earnings: Trevena Beats EPS for Q2 2024","id":129238409,"image":"","symbol":"TRVN","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592383758"},{"category":"company","date":1723116112,"headline":"Trevena: Q2 Earnings Snapshot","id":129234930,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"TRVN","publisher":"Yahoo","summary":"CHESTERBROOK, Pa. AP) — Trevena Inc. TRVN) on Thursday reported a loss of $4.9 million in its second quarter.","url":"https://finance.yahoo.com/news/trevena-q2-earnings-snapshot-112152620.html"},{"category":"company","date":1723114800,"headline":"Trevena Reports Second Quarter 2024 Results and Provides Business Update","id":129234931,"image":"https://s.yimg.com/ny/api/res/1.2/2gvMNNygNV5e1AaspcMgbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0yNzc-/https://media.zenfs.com/en/globenewswire.com/e0fcc3502771507a450882b6a41df7a8","symbol":"TRVN","publisher":"Yahoo","summary":"TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism of action in preclinical models $12 million financing completed, including non-dilutive $2 million tranche and $10 million reduction in liabilities associated with existing ex-US royalty financing CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical","url":"https://finance.yahoo.com/news/trevena-reports-second-quarter-2024-110000025.html"},{"category":"company","date":1723100340,"headline":"Trevena GAAP EPS of -$0.23","id":129238412,"image":"","symbol":"TRVN","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3591803439"},{"category":"company","date":1723098960,"headline":"Buy Rating Affirmed for Trevena Amid Strong TRV-045 Development Progress and Stable Financial Position","id":129276566,"image":"","symbol":"TRVN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3593080461"},{"category":"company","date":1723097820,"headline":"Trevena reports Q2 EPS (23c) vs. (69c) last year","id":129238413,"image":"","symbol":"TRVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3591764840"},{"category":"company","date":1723093380,"headline":"Trevena announces 1-for-25 reverse stock split","id":129276568,"image":"","symbol":"TRVN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592868096"},{"category":"company","date":1722513600,"headline":"Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors","id":129063661,"image":"https://s.yimg.com/ny/api/res/1.2/PRmGIJi0iwjeNwp2eG1GFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00NDE-/https://media.zenfs.com/en/globenewswire.com/f62671a6941ad62a5569bf4eb2a2514a","symbol":"TRVN","publisher":"Yahoo","summary":"SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024. “We are thrilled to welcome Anne and Jennifer to our boar","url":"https://finance.yahoo.com/news/sagimet-biosciences-announces-appointment-anne-120000592.html"}]}